Hughes Helen, Leane Michael M, Tobyn Michael, Gamble John F, Munoz Santiago, Musembi Pauline
Drug Product Science and Technology, Bristol-Myers Squibb, Reeds Lane, Moreton, Wirral, CH46 1QW, UK,
AAPS PharmSciTech. 2015 Feb;16(1):165-70. doi: 10.1208/s12249-014-0215-7. Epub 2014 Sep 19.
Bulk density can be a key indicator of performance, and may influence choice of formulation route of materials in pharmaceutical development. During early development, the cost of API's can be expensive and the availability of material for powder property analysis is limited. The aim of this work was to investigate a suitable small-scale, low material requirement, bulk density test which would provide comparable data to the recommended large volume USP test. Materials with a range of morphological characteristics typically seen in the pharmaceutical industry were assessed to ensure that methods were suitably robust. It was found that the USP II "low volume" test does not give equivalent results to other tests in the USP, across the range of materials. An alternative test based on the FT4 powder rheometer at a scale of 25 mL gave results equivalent to the large volume USP I standard test. The use of smaller 10-mL methods was also found to give acceptable results for materials that were considered well-behaved but were more variable with difficult to handle materials with low bulk density.
堆密度可能是性能的关键指标,并且可能会影响药物研发中材料制剂途径的选择。在早期研发阶段,活性药物成分(API)的成本可能很高,而且用于粉末特性分析的材料有限。这项工作的目的是研究一种合适的小规模、低材料需求的堆密度测试方法,该方法能够提供与推荐的大体积美国药典(USP)测试相当的数据。对制药行业中常见的一系列具有不同形态特征的材料进行了评估,以确保方法具有足够的稳健性。结果发现,USP II“低体积”测试在整个材料范围内,其结果与USP中的其他测试结果并不等效。基于FT4粉末流变仪的25 mL规模的替代测试,其结果与大体积USP I标准测试相当。对于那些认为性能良好的材料,使用较小的10 mL测试方法也能得到可接受的结果,但对于堆密度低且难以处理的材料,结果的变化更大。